#United States #Salt Lake City #Co-Diagnostics #PCR Testing #FDA Submission

Co-Diagnostics Advances Regulatory Journey with FDA Notification

Co-Diagnostics, Inc., a leading molecular diagnostics company based in Salt Lake City, has embarked on a significant milestone in its operations by submitting a Dual 510(k) premarket notification to the U.S. Food and Drug Administration (FDA). This strategic move also includes a concurrent CLIA Waiver by Application, intended for the use of its innovative Co-Dx™ PCR Flu A/B RSV upper respiratory multiplex test using the Co-Dx PCR Pro® instrument.

This submission is notable as it not only underscores the complete clinical and analytical performance studies that the company undertook, but also highlights its commitment to enhancing diagnostic accessibility at decentralized points of care. The Co-Dx PCR Pro® instrument is designed to offer patients easier access to essential testing, a requirement that has surged in demand in the current healthcare landscape.

As Dwight Egan, the CEO of Co-Diagnostics, asserted, the completion of this submission represents a pivotal moment in the company’s journey, reflecting years of dedication and investment in advancing the Co-Dx PCR platform. Egan emphasized that this move is a crucial advancement toward making PCR diagnostics more accessible, affordable, and user-friendly.

The importance of this submission is backed by extensive clinical research. The studies included data from over 1,400 symptomatic patients across nine varied U.S. clinical sites, alongside an analytical program involving 27 studies and more than 10,000 upper respiratory PCR test runs. A significant highlight of these studies was a multicenter reproducibility test which assessed performance across various operators and settings, reinforcing the test's reliability and effectiveness.

A successful CLIA Waiver by Application would enable the Co-Dx team to facilitate the use of this test in decentralized, waived point-of-care environments. Such changes are expected to dramatically improve access to molecular PCR testing, which has been traditionally confined to laboratory settings.

The innovation that sets the Co-Dx PCR platform apart is its blend of high-quality real-time PCR technology with a cost-effective instrument and consumable model. This platform integrates a pioneering cloud-based infrastructure to track localized outbreaks as they happen, an invaluable feature that distinguishes it from existing decentralized molecular systems. By putting this testing capability within closer reach of patients, the company aims to significantly expand its services into near-patient and decentralized testing environments.

It is important to note, however, that the Co-Dx PCR platform—including the PCR Home®, PCR Pro®, its mobile application, and all related tests—remains subject to review by the FDA and/or other regulatory bodies and is not currently available for sale.

In summary, Co-Diagnostics, Inc. continues to lead the charge in molecular diagnostics through innovative technology aimed at improving public health. With their recent steps towards FDA approval, they stand poised to make a lasting impact on the landscape of testing for upper respiratory illnesses. As the healthcare industry evolves, the role of decentralized diagnostics will only grow, and Co-Dx is at the forefront of this transformation.

For more details about the company and its offerings, visit Co-Diagnostics.